Hjalte Rasmussen

Q: What Schools Are Affiliated With Hjalte Rasmussen

Hjalte Rasmussen is affiliated with the following schools: College of Europe, University of Sydney, University of Copenhagen

Hjalte Rasmussen's AcademicInfluence.com Rankings

Hjalte Rasmussen

Law

#2176

World Rank

#2721

Historical Rank

International Law

#1003

World Rank

#1209

Historical Rank

law Degrees

Download Badge

Why Is Hjalte Rasmussen Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Hjalte Rasmussen was Professor of European Union Law at the University of Copenhagen. Previously he was a Professor of law at the Law Department of the Copenhagen Business School and a Visiting Professor at the College of Europe, at Bruges.

(See a Problem?)

Hjalte Rasmussen's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Regional Angiogenesis With Vascular Endothelial Growth Factor in Peripheral Arterial Disease: A Phase II Randomized, Double-Blind, Controlled Study of Adenoviral Delivery of Vascular Endothelial Growth Factor 121 in Patients With Disabling Intermittent Claudication (2003) (569)
Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. (1997) (380)
Sodium zirconium cyclosilicate in hyperkalemia. (2015) (359)
Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. (2014) (302)
Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF121 (AdVEGF121) versus maximum medical treatment (2006) (264)
Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. (1998) (237)
Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. (1998) (220)
INTRAVENOUS MAGNESIUM IN ACUTE MYOCARDIAL INFARCTION (1986) (208)
TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. (2004) (195)
Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. (2015) (188)
Acute renal failure. Multivariate analysis of causes and risk factors. (1982) (180)
Exaggeration of nonculprit stenosis severity during acute myocardial infarction: implications for immediate multivessel revascularization. (2002) (173)
Reversible Oxidative Modification: A Key Mechanism of Na+-K+ Pump Regulation (2009) (162)
Short-chain fatty acid production from mono- and disaccharides in a fecal incubation system: implications for colonic fermentation of dietary fiber in humans. (1988) (155)
Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS‐9) in heart failure patients: results from a phase 3 randomized, double‐blind, placebo‐controlled trial (2015) (137)
Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. (2002) (136)
Characterization of Structure and Function of ZS-9, a K+ Selective Ion Trap (2014) (135)
Field triage to primary angioplasty combined with emergency department bypass reduces treatment delays and is associated with improved outcome. (2007) (133)
Degradation of amino acids to short-chain fatty acids in humans. An in vitro study. (1988) (128)
Influence of magnesium substitution therapy on blood lipid composition in patients with ischemic heart disease. A double-blind, placebo controlled study. (1989) (127)
A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient (2015) (125)
Prediction of outcome in acute renal failure by discriminant analysis of clinical variables. (1985) (115)
Marimastat in patients with advanced pancreatic cancer: a dose-finding study. (1999) (110)
Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis. (2020) (104)
Magnesium deficiency in patients with ischemic heart disease with and without acute myocardial infarction uncovered by an intravenous loading test. (1988) (100)
A Phase I Trial of TNFerade Biologic in Patients with Soft Tissue Sarcoma in the Extremities (2004) (93)
Dofetilide, A Novel Class III Antiarrhythmic Agent (1992) (91)
Regional Angiogenesis with Vascular Endothelial Growth Factor (VEGF) in peripheral arterial disease: Design of the RAVE trial. (2003) (90)
TNFerade Biologic: Preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene (2002) (84)
Angiotensin II inhibits the Na+-K+ pump via PKC-dependent activation of NADPH oxidase. (2009) (83)
Radiation-induced tumour necrosis factor-alpha expression: clinical application of transcriptional and physical targeting of gene therapy. (2002) (83)
FXYD Proteins Reverse Inhibition of the Na+-K+ Pump Mediated by Glutathionylation of Its β1 Subunit* (2011) (82)
Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions. (2002) (82)
&bgr;3 Adrenergic Stimulation of the Cardiac Na+-K+ Pump by Reversal of an Inhibitory Oxidative Modification (2010) (82)
Magnesium infusion reduces the incidence of arrhythmias in acute myocardial infarction. A double‐blind placebo‐controlled study (1987) (79)
Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris. (1992) (78)
Glutathionylation Mediates Angiotensin II–Induced eNOS Uncoupling, Amplifying NADPH Oxidase‐Dependent Endothelial Dysfunction (2014) (78)
The electrophysiological effects of intravenous magnesium on human sinus node, atrioventricular node, atrium, and ventricle (1989) (76)
Value of two-dimensional echocardiography, electrocardiography, and clinical signs in detecting right ventricular infarction. (1986) (74)
Magnesium and acute myocardial infarction. Transient hypomagnesemia not induced by renal magnesium loss in patients with acute myocardial infarction. (1986) (74)
Effect of osmotic swelling and shrinkage on Na(+)-K+ pump activity in mammalian cardiac myocytes. (1993) (72)
Hyperaldosteronemia in rabbits inhibits the cardiac sarcolemmal Na(+)-K(+) pump. (2000) (71)
Apical sparing in tako‐tsubo cardiomyopathy (2006) (71)
Connections: heart disease, cellular electrophysiology, and ion channels (1992) (70)
Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter. (1992) (66)
Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man. (1992) (65)
Angiotensin-converting enzyme inhibitors regulate the Na(+)-K+ pump via effects on angiotensin metabolism. (1996) (64)
Adenoviral-mediated gene transfer of vascular endothelial growth factor in critical limb ischemia: safety results from a phase I trial (2003) (63)
Na+ influx and Na(+)-K+ pump activation during short-term exposure of cardiac myocytes to aldosterone. (1998) (62)
A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer. (2002) (60)
Clinical and electrophysiologic effects of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with angina pectoris. (1992) (60)
The first‐in‐man randomized trial of a beta3 adrenoceptor agonist in chronic heart failure: the BEAT‐HF trial (2017) (58)
The nitric oxide donor sodium nitroprusside stimulates the Na+–K+ pump in isolated rabbit cardiac myocytes (2005) (58)
Reversible oxidative modification: implications for cardiovascular physiology and pathophysiology. (2010) (58)
Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Dofetilide Arrhythmia Study Group. (1995) (57)
Angiotensin-converting enzyme inhibition, intracellular Na+, and Na(+)-K+ pumping in cardiac myocytes. (1995) (56)
An in vitro study of short-chain fatty acid concentrations, production and absorption in pig (Sus scrofa) colon. (1992) (55)
Activation of cAMP-dependent Signaling Induces Oxidative Modification of the Cardiac Na+-K+ Pump and Inhibits Its Activity* (2010) (54)
Hemodynamic effects of intravenously administered magnesium on patients with ischemic heart disease (1988) (53)
Prevalence of coronary occlusion and outcome of an immediate invasive strategy in suspected acute myocardial infarction with and without ST-segment elevation. (2002) (51)
Myeloid progenitor cell proliferation and mobilization effects of BB10010, a genetically engineered variant of human macrophage inflammatory protein-1alpha, in a phase I clinical trial in patients with relapsed/refractory breast cancer. (1998) (50)
Electrogenic Li+/Li+ exchange mediated by the Na+-K+ pump in rabbit cardiac myocytes. (1997) (50)
Siglec-8 antibody reduces eosinophil and mast cell infiltration in a transgenic mouse model of eosinophilic gastroenteritis. (2019) (49)
Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication. (2002) (49)
Voltage-dependent stimulation of the Na(+)-K(+) pump by insulin in rabbit cardiac myocytes. (2000) (48)
One‐year death rate in 270 patients with suspected acute myocardial infarction, initially treated with intravenous magnesium or placebo (1988) (48)
Oxidative regulation of the Na(+)-K(+) pump in the cardiovascular system. (2012) (43)
Susceptibility of β1 Na+-K+ Pump Subunit to Glutathionylation and Oxidative Inhibition Depends on Conformational State of Pump* (2012) (43)
Mechanisms of Na+-K+pump regulation in cardiac myocytes during hyposmolar swelling. (1999) (42)
Quantitative calculation of the role of the Na(+),K(+)-ATPase in thermogenesis. (2013) (42)
Inhibition of Na‐K Pump Current in Guinea Pig Ventricular Myocytes by Dihydroouabain Occurs at High‐ and Low‐Affinity Sites (1989) (39)
Serum methylmalonic acid in uraemia. (1992) (39)
Pharmacokinetic and pharmacodynamic effects of UK-68,798, a new potential class III antiarrhythmic drug. (1991) (38)
Amiodarone inhibits the Na(+)-K+ pump in rabbit cardiac myocytes after acute and chronic treatment. (1998) (35)
Alloxan-induced diabetes reduces sarcolemmal Na+-K+ pump function in rabbit ventricular myocytes. (2007) (35)
The influence of ispaghula husk and lactulose on the in vivo and the in vitro production capacity of short-chain fatty acids in humans. (1987) (35)
The use of beta3-adrenergic receptor agonists in the treatment of heart failure. (2009) (34)
Opposing effects of coupled and uncoupled NOS activity on the Na+-K+ pump in cardiac myocytes. (2008) (33)
Effect of dofetilide on cardiac repolarization in patients with ventricular tachycardia. A study using simultaneous monophasic action potential recordings from two sites in the right ventricle. (1994) (33)
Angiotensin regulates the selectivity of the Na+-K+ pump for intracellular Na. (1999) (32)
HMG CoA reductase inhibition reduces sarcolemmal Na(+)-K(+) pump density. (2000) (31)
Protein kinase Cɛ contributes to regulation of the sarcolemmal Na+-K+ pump (2001) (29)
Natriuretic peptides stimulate the cardiac sodium pump via NPR-C-coupled NOS activation. (2008) (29)
Two stable levels of diastolic potential at physiological K+ concentrations in human ventricular myocardial cells. (1990) (29)
An Open-Label, Proof-of-Concept Study of Lirentelimab for Antihistamine-Resistant Chronic Spontaneous and Inducible Urticaria. (2021) (28)
Inhibition of electrogenic Na(+)-pumping in isolated atrial tissue from patients treated with digoxin. (1990) (27)
Lactulose detoxifies in vitro short-chain fatty acid production in colonic contents induced by blood: implications for hepatic coma. (1988) (27)
VEGF gene therapy for coronary artery disease and peripheral vascular disease. (2002) (26)
β3-Adrenoceptor activation relieves oxidative inhibition of the cardiac Na+-K+ pump in hyperglycemia induced by insulin receptor blockade. (2015) (26)
A dose-ranging study of UK-68,798, a novel class III anti-arrhythmic agent, in normal volunteers. (1991) (25)
Dietary cholesterol affects Na+-K+ pump function in rabbit cardiac myocytes. (1997) (25)
Redox-dependent regulation of the Na⁺-K⁺ pump: new twists to an old target for treatment of heart failure. (2013) (25)
Sodium‐hydrogen exchange in guinea‐pig ventricular muscle during exposure to hyperosmolar solutions. (1991) (24)
A Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Phase 1 Study of AK002, a Novel Siglec-8 Selective Monoclonal Antibody, in Healthy Subjects (2018) (24)
Dietary cholesterol alters Na+/K+ selectivity at intracellular Na+/K+ pump sites in cardiac myocytes. (2004) (23)
Dependence of Na+-K+ pump current-voltage relationship on intracellular Na+, K+, and Cs+ in rabbit cardiac myocytes. (2002) (23)
Protein kinase‐dependent oxidative regulation of the cardiac Na+–K+ pump: evidence from in vivo and in vitro modulation of cell signalling (2013) (21)
New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval. (2016) (21)
Na+ influx and Na+-K+pump activation during short-term exposure of cardiac myocytes to aldosterone. (1998) (21)
Regulation of intracellular pH in cardiac muscle during cell shrinkage and swelling in anisosmolar solutions. (1994) (20)
Influence of oral magnesium supplementation on cardiac events among survivors of an acute myocardial infarction. (1993) (20)
Short-chain fatty acids in bowel contents after intestinal surgery. (1989) (20)
Identification of electric-field-dependent steps in the Na(+),K(+)-pump cycle. (2014) (19)
Inhibition of electrogenic Na-pumping attributable to binding of cardiac steroids to high-affinity pump sites in human atrium. (1985) (18)
Stimulation of the cardiac myocyte Na+-K+ pump due to reversal of its constitutive oxidative inhibition. (2015) (18)
Multivariate Analysis of Causes and Risk Factors (1992) (17)
The effect of intravenous magnesium therapy on serum and urine levels of potassium, calcium, and sodium in patients with ischemic heart disease, with and without acute myocardial infarction. (1988) (17)
β-Adrenergic regulation of the cardiac Na+-K+ ATPase mediated by oxidative signaling. (2012) (17)
Prediction of Outcome in Acute Renal Failure by Discriminant Analysis of Clinical Variables (1986) (16)
Angiogenic gene therapy strategies for the treatment of cardiovascular disease. (2002) (16)
Na+-dependent activation of Na+-K+ pump in human myocardium during recovery from acidosis. (1989) (16)
A randomized phase II study of BB‐10010: a variant of human macrophage inflammatory protein‐1α for patients receiving high‐dose etoposide and cyclophosphamide for malignant lymphoma and breast cancer (1997) (15)
Natriuretic Peptides Stimulate the Cardiac Sodium Pump via NPR-C Coupled NOS Activation (2007) (14)
New agents for hyperkalemia. (2015) (13)
Myocardial contractility and performance capacity after magnesium infusions in young healthy persons: A double‐blind, placebo‐controlled, cross‐over study (1988) (13)
Extracellular allosteric Na(+) binding to the Na(+),K(+)-ATPase in cardiac myocytes. (2013) (11)
Myocardial cation transport. (1993) (11)
Short chain fatty acids in inflammatory bowel disease. The effect of bacterial fermentation of blood. (1988) (11)
Glutathionylation-Dependence of Na(+)-K(+)-Pump Currents Can Mimic Reduced Subsarcolemmal Na(+) Diffusion. (2016) (11)
Decomposition of wheat bran and ispaghula husk in the stomach and the small intestine of healthy men. (1988) (11)
Silencing overexpression of FXYD3 protein in breast cancer cells amplifies effects of doxorubicin and γ-radiation on Na+/K+-ATPase and cell survival (2016) (11)
Membrane accessibility of glutathione. (2015) (10)
Kinetic comparisons of heart and kidney Na+,K(+)-ATPases. (2012) (9)
Determination of Biopsy Yield That Optimally Detects Eosinophilic Gastritis and/or Duodenitis in a Randomized Trial of Lirentelimab. (2021) (9)
Routine aspiration thrombectomy improves the diagnosis and management of embolic myocardial infarction (2016) (9)
Thyroid status and Na(+)-K+ pump current, intracellular sodium, and action potential duration in rabbit heart. (1995) (9)
Cyclosporine and FK506 differentially regulate the sarcolemmal Na(+)-K(+) pump. (2001) (9)
Batimastat and Marimastat in Cancer (1999) (9)
Procedural and in-patient outcomes in patients aged 80 years or older undergoing contemporary primary percutaneous coronary intervention. (2012) (9)
P152 CLINICAL ACTIVITY OF AK002, AN ANTI-SIGLEC-8 ANTIBODY, IN MULTIPLE FORMS OF UNCONTROLLED CHRONIC URTICARIA (2019) (8)
929b Larazotide Acetate, a First In-Class, Novel Tight Junction Regulator, Meets Primary Endpoint and Significantly Reduces Signs and Symptoms of Celiac Disease in Patients on a Gluten-Free Diet: Results of a Multicenter, Randomized, Placebo Controlled Trial (2014) (8)
Evidence for electrogenic Na+ pumping in human atrial myocardium. (1984) (7)
"Don't flog the heart!" - development of specific drug therapies for heart failure. (2007) (7)
Characterization of a sodium pump-induced hyperpolarization in isolated human atrium. (1986) (7)
Thyroid status and regulation of intracellular sodium in rabbit heart. (1997) (7)
A primary stenting strategy as an alternative to fibrinolytic therapy in acute myocardial infarction: An analysis of results in hospital and at 6 weeks and 6 months (1999) (7)
Glutathionylation of erythrocyte Na–K pump in heart failure: a novel biomarker that reflects a key oxidative abnormality in the heart (2012) (6)
Clinical intervention studies on magnesium in myocardial infarction. (1989) (6)
Looking into anti-angiogenic gene therapies for disorders of the eye. (2001) (6)
Trial of a trial by media (2001) (6)
AK002, an Anti-Siglec-8 Antibody, Depletes Tissue Eosinophils and Improves Dysphagia Symptoms in Patients with Eosinophilic Esophagitis (2020) (6)
Targeting Cardiac Myocyte Na+-K+ Pump Function With β3 Adrenergic Agonist in Rabbit Model of Severe Congestive Heart Failure (2020) (6)
Chronic amiodarone-induced inhibition of the Na+-K+ pump in rabbit cardiac myocytes is thyroid-dependent: comparison with dronedarone. (2003) (6)
Outcomes by day and night for patients bypassing the emergency department presenting with ST-segment elevation myocardial infarction identified with a pre-hospital electrocardiogram. (2015) (5)
Left bundle branch block without concordant ST changes is rarely associated with acute coronary occlusion. (2013) (5)
Phase 1b Study of AK002, an Anti-Siglec-8 Monoclonal Antibody, in Patients with Severe Allergic Conjunctivitis (KRONOS Study) (2020) (5)
A randomized phase II study of BB-10010: a variant of human macrophage inflammatory protein-1alpha for patients receiving high-dose etoposide and cyclophosphamide for malignant lymphoma and breast cancer. (1997) (5)
A randomized double blind placebo controlled multicenter pilot study of the safety and feasibility of AdGVVEGF121.10 via an intramyocardial injection catheter in patients with advanced coronary artery disease (2003) (4)
Justification for intravenous magnesium therapy in acute myocardial infarction. (1988) (4)
Procedural and In-patient Outcomes in Patients Aged 80 Years or Older Undergoing Contemporary Primary Percutaneous Coronary Intervention (2012) (4)
Thermodynamic energy stability and in vitro potassium exchange capacity of ZS-9, a novel selective cation trap for the treatment of hyperkalemia (2014) (4)
Protein kinase Cepsilon contributes to regulation of the sarcolemmal Na(+)-K(+) pump. (2001) (4)
Abstract 17142: Treatment With a Beta3 Adrenergic Receptor Agonist in Heart Failure Reverses an Oxidative Modification and Inhibition of the Na+-K+ Pump in Cardiac Myocytes and Improves Pulmonary Congestion (2013) (4)
ACID BASE, ION DISORDERS, LITHISASIS (2014) (3)
FO012NORMALIZATION OF SERUM BICARBONATE WITH SODIUM ZIRCONIUM CYCLOSILICATE (ZS-9) IN THE PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED HARMONIZE STUDY (2015) (3)
[Colloids versus crystalloids in the treatment of hypovolemic or septic shock]. (1989) (3)
Angiotensin regulates the selectivity of the Na 1K 1 pump for intracellular Na 1 (1999) (3)
Clinical Activity of AK002, an Anti-Siglec-8 Monoclonal Antibody, in Treatment-Refractory Chronic Urticaria (2020) (3)
Mechanisms of Na+-K+ pump regulation in cardiac myocytes during hyposmolar swelling. (1999) (3)
5-(N,N-dimethyl)amiloride-sensitive Na-Li exchange in isolated specimens of human atrium. (1988) (3)
Justification for magnesium therapy in acute ischaemic heart disease. Clinical and experimental studies. (1993) (3)
D451 CLINICAL ACTIVITY OF AK002, AN ANTI-SIGLEC-8 ANTIBODY, IN SEVERE ALLERGIC CONJUNCTIVITIS AND COMORBID ATOPIC DISEASES (2019) (3)
Oxidative regulation of the Na+ -K+ pump in cardiac physiology and pathology: clarifying the published evidence. (2013) (2)
ZS-9 MAINTAINS NORMOKALEMIA IN HYPERKALEMIC PATIENTS DESPITE CONTINUING RAAS INHIBITORS: A SUBGROUP ANALYSIS FROM A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL (2015) (2)
Fr198 GASTRODUODENAL EOSINOPHILIA IS UNDER-APPRECIATED IN EOSINOPHILIC ESOPHAGITIS (EOE) PATIENTS WITH FUNCTIONAL BOWEL SYMPTOMS: A REAL LIFE EXPERIENCE (2021) (2)
[PP.35.03]: SODIUM ZIRCONIUM CYCLOSILICATE FOR TREATMENT OF HYPERKALAEMIA ANALYSIS OF PATIENTS ON RENIN-ANGIOTENSIN-ALDOSTERONE INHIBITORS (RAASI) FROM THE PHASE 3 HARMONIZE STUDY (2015) (2)
ZS-9, A NOVEL SELECTIVE CATION TRAP, LEADS TO A RAPID AND PREDICTABLE RATE OF DECLINE IN SERUM POTASSIUM IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND HYPERKALEMIA (2014) (2)
TREATMENT OF HYPERKALEMIA WITH ZS-9, A SELECTIVE NONABSORBED CATION EXCHANGE RESIN, DOES NOT LEAD TO HYPOMAGNESEMIA: RESULTS FROM TWO MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 TRIALS (2015) (2)
Abstract 13555: Acute Efficacy of Sodium Zirconium Cyclosilicate (ZS-9) in Patients on Mineralocorticoid-Receptor Antagonists: Analysis From Two Phase 3 Studies (2015) (2)
Voltage‐Dependent Inhibition of the Na+‐K+ Pump by Intracellular Potassium in Rabbit Venticular Myocytes (1997) (2)
Effect of ZS-9, a novel selective cation trap, on urinary potassium and sodium excretion when used for the treatment of hyperkalemia in patients with chronic kidney disease (2014) (2)
ACUTE-PHASE EFFICACY OF ZS-9 IN PATIENTS WITH BASELINE SERUM POTASSIUM LEVELS ABOVE 5.5 MEQ/L: ANALYSIS FROM A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL (2015) (2)
On the effect of unstirred layers on K+-activated electrogenic Na+ pumping in cardiac Purkinje strands. (1986) (2)
932 HISTOLOGIC AND SYMPTOMATIC IMPROVEMENT ACROSS MULTIPLE FORMS OF EOSINOPHILIC GASTROINTESTINAL DISEASES IN ENIGMA, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ANTOLIMAB (AK002) (2020) (2)
Abstract 16278: {beta}3 Adrenergic Stimulation Protects Against eNOS Uncoupling, Oxidative Na+-K+ Pump Inhibition and Vascular Dysfunction in Type 2 Diabetes (2012) (2)
Sodium zirconium cyclosilicate (ZS-9) treatment in patients with serum potassium >6.5 mEq/L (2015) (2)
Batimastat and Marimastat in Cancer: Summary of Early Clinical Data (1998) (2)
S-glutathionylation of the Na +-K + pump: a novel redox mechanism in preeclampsia. (2020) (1)
RAPID ONSET OF POTASSIUM:LOWERING WITH SODIUM ZIRCONIUM CYCLOSILICATE (ZS-9) ACROSS PATIENTS STRATIFIED BY RACE, AGE, AND COMORBIDITIES IN THE RANDOMIZED, DOUBLE:BLIND, PLACEBO:CONTROLLED PHASE 3 HARMONIZE STUDY (2016) (1)
Fr178 ACTIVATED MAST CELLS AND EOSINOPHILS ARE ASSOCIATED WITH INCREASED INFLAMMATORY MEDIATORS IN MUCOSAL BIOPSIES FROM PATIENTS WITH CHRONIC GASTROINTESTINAL SYMPTOMS (2021) (1)
1246 Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis Endure a Lengthy Path to Diagnosis and Experience Persistent Symptoms After Diagnosis (2019) (1)
ZS-9 once-daily maintained serum K+ in hyperkalemic subjects on RAAS therapy: subgroup analysis from a phase 3, multicenter, randomized, double-blind, placebo-controlled trial (2014) (1)
FP007EFFICIENCY OF SODIUM ZIRCONIUM CYCLOSILICATE (ZS-9) INCREASES WITH SEVERITY OF HYPERKALAEMIA: SUBGROUP ANALYSIS OF PATIENTS STRATIFIED BY BASELINE POTASSIUM IN THE PHASE 3 HARMONIZE STUDY (2015) (1)
Electrophysiological Effects of Intravenous UK-68, 798, a New Class III Antiarrhythmic Agent (1991) (1)
FP010MAINTENANCE OF NORMAL SERUM POTASSIUM WITH SODIUM ZIRCONIUM CYCLOSILICATE (ZS-9) IN SUBGROUP OF PATIENTS WITH HISTORY OF CHRONIC KIDNEY DISEASE AND ON RAAS INHIBITORS FROM THE PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED HARMONIZE STUDY (2015) (1)
[Short chain fatty acids in the human large intestine. The significance for gastrointestinal health and disease]. (1988) (1)
EFFECT OF SODIUM ZIRCONIUM CYCLOSILICATE (ZS-9) ON URINARY POTASSIUM AND SODIUM: AN ANALYSIS OF THE PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED HARMONIZE STUDY (2015) (1)
539 LONG-TERM TREATMENT OF PATIENTS WITH EOSINOPHILIC GASTRITIS AND/OR EOSINOPHILIC DUODENITIS WITH LIRENTELIMAB, A MONOCLONAL ANTIBODY AGAINST SIGLEC-8 (2021) (1)
ACHIEVEMENT AND MAINTENANCE OF NORMOKALAEMIA IN PATIENTS WITH NON-DIALYSIS STAGE 5 CHRONIC KIDNEY DISEASE (2015) (1)
FP008ACHIEVEMENT OF NORMAL SERUM POTASSIUM WITH SODIUM ZIRCONIUM CYCLOSILICATE (ZS-9) IN A SUBGROUP OF PATIENTS WITH STAGE 4/5 CHRONIC KIDNEY DISEASE AND BASELINE POTASSIUM ≥5.5 MMOL/L FROM THE PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED HARMONIZE STUDY (2015) (1)
Tu1251 MAST CELLS ARE SIGNIFICANTLY ACTIVATED IN PATIENTS WITH ULCERATIVE COLITIS AND ARE INHIBITED BY AN ANTI-SIGLEC-8 ANTIBODY, ANTOLIMAB (AK002) (2020) (1)
EoE Biopsies have Elevated and Activated Mast Cells that Produce Cytokines and Chemokines that Drive Disease Pathogenesis (2020) (1)
Change from baseline in serum K+ with ZS-9 in patients with chronic kidney disease treated for hyperkalemia (2014) (1)
1247 Development of a Patient Reported Outcome (PRO) Questionnaire to Assess the Symptoms of Eosinophilic Gastritis and Gastroenteritis (EG/EGE-SQ©) (2019) (1)
257 Sodium Zirconium Cyclosilicate for Patients With Severe Hyperkalemia: Subgroup Analysis of the Phase 3, International, Multicenter, Randomized, Double-Blind, Placebo-Controlled HARMONIZE Trial (2015) (1)
ZS-9 for treatment of hyperkalemia in black patients: subgroup analysis from the phase 3 HARMONIZE study (2015) (1)
The effectiveness of ZS-9 in achieving normokalemia during the open-label phase of the HARMONIZE trial (2015) (1)
Long-term safety and efficacy of intramuscular administration of Cl-1023 (AdGVVEGF121.10) in patients with intermittent claudication (2002) (1)
Treatment with a beta3 Adrenergic Receptor Agonist in Heart Failure Reverses Inhibition of the Na+–K+ Pump in Cardiac Myocytes and Improves Pulmonary Congestion (2013) (1)
Glutathionylation of the β1 Subunit Prevents the E1Na3 to E2P Forward Reaction in the Na+, K+ ATPase (2014) (1)
The “Obesity Paradox” in a Contemporary ST Elevation Myocardial Infarction (STEMI) Cohort (2016) (1)
Abstract 1379: Angiotensin II Inhibits the Na+-K+ pump via PKC-dependent Activation of NAD(P)H Oxidase (2008) (1)
Activation of sodium-hydrogen exchange in heart cells by hyperosmolar solutions (1990) (1)
Redox Regulation of Na+–K+ Pump in Vascular Smooth Muscle Cells: Implications for Vascular Tone in Heath and Disease (2012) (1)
Does emergency triage of acute myocardial infarction (ETAMI) increase unnecessary coronary angiography? A 5-year comparison of Field Triage versus Emergency Department Triage (2009) (1)
The Impact of Aspiration Thrombectomy on the Diagnosis and Outcomes of Coronary Embolism (2011) (1)
Emergency surgery for AMI patients with fibrinolysis failure or contraindication not suitable for percutaneous intervention (2000) (0)
1009-47 Effect of Insulin on Electrogenic Na+-K+ Pump Current in Isolated Rabbit Ventricular Myocytes (1995) (0)
Consideration of natriuretic peptide receptor C. (2011) (0)
Spontaneous Coronary Artery Dissection: A Single Centre Case Series (2012) (0)
Angiotensin regulates the selectivity of the Na+-K+ pump for intracellular Na+. (1999) (0)
The Changing Face of STEMI Patients – Then and Now (2016) (0)
From Bench-Based PhD Project to First-in-Man Use of β3 Adrenergic Agonist in Patients with Treatment-Resistant Decompensated Congestive Heart Failure (2017) (0)
Beta3 adrenergic stimulation confers trophoblast protection against oxidative damages from hypoxia-reoxygenation injury through the endothelial nitric oxide synthase-mediated NADPH oxidase signaling pathway (2021) (0)
Not all cardiac glycosides are equal: Could ouabain prove to be better than digoxin for heart failure? (2015) (0)
Na+/K+-ATPase-associated FXYD3 Protein As An Intracellular Therapeutic Target in Cancer (2020) (0)
Antioxidant Effect of Beta-1 Adrenergic Receptor Blockade Through Macromolecular Remodelling of An Oxidative Pathway: New Tricks of An Old Dog (2012) (0)
Selective Activation of β3 Adrenoceptors Protects Against Type 2 Diabetes-induced eNOS Uncoupling, Oxidative Na+–K+ Pump Inhibition and Vascular Dysfunction (2013) (0)
Extracellular Allosteric Na D Binding to the Na D ,K D -ATPase in Cardiac Myocytes (2013) (0)
Raised Neutrophil-Lymphocyte Ratio following acute STEMI is associated with increased rates of Re-infarction and Mortality at 1 year (2015) (0)
A cautionary tale for multivessel stenting during acute myocardial infarction: Significant vasoconstriction of non-culprit lesions (2003) (0)
Can acute myocardial infarction be predicted on presentation in patients with persistent chest pain without significant ST segment elevation (2003) (0)
The N-3 polyunsaturated fatty acid eicosapentanoic acid (EPA) stimulates the NaK pump in rabbit cardiac myocytes (2000) (0)
Co-location of a private cardiac catheter laboratory within a university teaching hospital: An initial six month experience (2000) (0)
Nitric Oxide-Activated Guanylyl Cyclase Modulates NAD(P)H Oxidase and Oxidative Inhibition of the Na+–K+ Pump in Ventricular Myocytes in a Phosphatase Dependent Manner (2009) (0)
Primary Percutaneous Coronary Intervention is associated with less myocardial injury in an older population (2009) (0)
A dose-ranging study ofUK-68,798, anovel class III anti-arrhythmic agent, innormal volunteers (1991) (0)
Metoprolol Stimulates the Cardiac Na+–K+ Pump by Reducing the Baseline Glutathiolynation of its beta1 Subunit (2010) (0)
Glutathionylation Mediates Angiotensin II-induced Uncoupling of Endothelial Nitric Oxide Synthase and Endothelial Dysfunction (2012) (0)
847 Lactate to Albumin Ratio (LAR) Predicts In-Hospital Mortality in Patients Presenting With ST Elevation Myocardial Infarction (STEMI) (2020) (0)
Silencing FXYD3 protein enhances cytotoxicity effect of doxorubicin and gamma irradiation in human breast cancer cells (2014) (0)
Inhibition of Na+-K+ pumping in human tissue by cardiac steroids (1994) (0)
Field Triage Reduces the Incidence and Mortality of Ischaemic Cardiogenic Shock in Patients with Acute Myocardial Infarction (2010) (0)
Myocardial injury following Primary Percutaneous Coronary Intervention (PCI) is comparable in patients with multi-vessel disease compared to single vessel disease (2009) (0)
(cid:1) 3 Adrenergic Stimulation of the Cardiac Na (cid:2) -K (cid:2) Pump by Reversal of an Inhibitory Oxidative Modification (2010) (0)
In vivo Function and Oxidative Modification of the Na+–K+ Pump in an Infarct Model of Heart Failure (2012) (0)
Incidence, Risk Factors, and In-Hospital Mortality of Contrast-Induced Nephropathy in Field Triaged Patients with Acute Myocardial Infarction (2010) (0)
Ventricular Myocardial Cells (2005) (0)
Field Triage for ST Elevation Myocardial Infarction Reduces the Incidence of Cardiogenic Shock and Subsequent In-patient Mortality (2012) (0)
Urgent transfer of rural and district hospital AMI patients with fibrinolysis failure or contraindication for immediate coronary angiography ± intervention is feasible and safe (2000) (0)
Abstract 177: Promotion Of Nitroso-redox Balance By Beta 3 Adrenoceptor Agonism: Therapeutic Implications For Cardiovascular Complications Of Diabetes (2014) (0)
Treatment with β3 adrenergic agonists reverses impaired cardiac myocyte Na+ export and improves severely decompensated heart failure; a clinical application of an experimental finding (2019) (0)
β3 Adrenergic Receptor Stimulates the Cardiac Na/K Pump via an NO-dependent Pathway and Reduces Oxidative Modification of the β1 Pump Subunit (2009) (0)
In vivo effect of aldosterone on the cardiac Na+-K+ pump (1998) (0)
Electrocardiographic features of left circumflex coronary artery occlusion in patients presenting with acute myocardial infarction (2000) (0)
A novel kinetic model based on the Albers-Post scheme that mimics the behaviour of the Na+, K+-ATPase in situ (2015) (0)
Mo1236 MAST CELL LEVEL AND CLINICAL CORRELATES IN PATIENS WITH EOSINOPHILIC GASTRITIS AND GASTROENTERITIS (2020) (0)
Abstract 503: Maintenance of Normokalemia with ZS-9 Once Daily in CHF Patients on RAAS Inhibitors: Subgroup Analysis of a Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Hyperkalemia (2014) (0)
Acute Coronary Collaterals Reduce Mortality and Improve Left Ventricular Function in Patients Presenting with ST Elevation Myocardial Infarction (STEMI) (2019) (0)
867 EGID BIOPSIES HAVE FUNCTIONALLY DISTINCT AND ACTIVATED MAST CELLS THAT CONTRIBUTE TO DISEASE PATHOGENESIS AND ARE INHIBITED BY AN ANTI-SIGLEC-8 ANTIBODY, ANTOLIMAB (AK002) (2020) (0)
Miscellaneous Acute Renal Failure: Multivariate Analysis of Causes and Risk Factors (1983) (0)
Fr173 OPTIMIZATION OF EOSINOPHILIC GASTRITIS/DUODENITIS DETECTION REQUIRES EVALUATION OF MULTIPLE HIGH-POWERED FIELDS IN EACH OF 8 GASTRIC AND 4 DUODENAL BIOPSIES: ANALYSIS FROM A RANDOMIZED TRIAL (2021) (0)
P0620OXIDANT-INDUCED RENAL PRECONDITIONING BIOMARKERS FOR AKI PREVENTION WITH RBT-1 (2020) (0)
Abstract 509: Thermodynamic Energy Stability and In Vitro Potassium Exchange by ZS-9, a Novel Selective Cation Trap for Treatment of Hyperkalemia (2014) (0)
CKD PATHOPHYSIOLOGY AND CLINICAL STUDIES (2014) (0)
Mo1237 ESTABLISHMENT OF NORMAL TISSUE MAST CELL LEVELS IN GASTRIC AND DUODENAL BIOPSIES OF PATIENTS WTHOUT GASTROINTESTINAL DISEASE (2020) (0)
cGMP Compartmentalization Accounts for the Bi-phasic Effect of ANP on Na+–K+ Pump in Cardiac Myocytes (2009) (0)
[Magnesium and cardiovascular disease. I. Do patients with ischemic heart disease suffer from magnesium deficiency?]. (1988) (0)
Ouabain-Induced Stimulation of Sodium Potassium Pump Activity is Transient in Cardiac Myocytes (2018) (0)
Structure of ZS-9. (2014) (0)
1244 Symptomatic Patients Suspected of Eosinophilic Gastritis and/or Enteritis Have Elevated Mucosal Mast Cell Counts Without Eosinophilia: A New Diagnostic Entity? (2019) (0)
Fr191 EOSINOPHILIC GASTRITIS AND EOSINOPHILIC DUODENITIS EXHIBIT A SIMILAR CLINICAL PRESENTATION, UNDERSCORING THE NEED FOR COLLECTION OF MULTIPLE BIOPSIES FROM BOTH THE STOMACH AND DUODENUM TO EVALUATE FOR TISSUE EOSINOPHILIA: ANALYSIS FROM A RANDOMIZED TRIAL (2021) (0)
Mo1163 – Eg and Eoe Patient Biopsies Have High Numbers of Activated Eosinophils and Mast Cells that are Inhibited by Ak002 (2019) (0)
Abstract 16681: Effect of ZS-9 Treatment for Hyperkalemia in Patients With Heart Failure Receiving Maximal, Submaximal or no Renin-angiotensin-aldosterone-system Inhibitors: Pooled Analysis From Two Phase III Trials (2016) (0)
P159 PHENOTYPIC CHARACTERIZATION OF INFLAMMATORY BOWEL DISEASE BIOPSIES REVEAL THAT MAST CELLS ARE SIGNIFICANTLY ELEVATED AND ACTIVATED IN PATIENTS WITH ULCERATIVE COLITIS (2020) (0)
Methods and compositions for treating myocardial affections (2005) (0)
Mo1127 – Mast Cells in Addition to Eosinophils are Markedly Elevated At Baseline in Patients with Eosinophilic Gastritis And/Or Gastroenteritis (2019) (0)
Models of colonic short chain fatty acid transport (1988) (0)
Fr176 ENDOSCOPIC APPEARANCE DOES NOT PREDICT THE PRESENCE OF HISTOLOGIC EOSINOPHILIC GASTRITIS AMONG SYMPTOMATIC ADULTS, INDICATING THAT COLLECTION AND EVALUATION OF BIOPSIES SHOULD OCCUR REGARDLESS OF ENDOSCOPIC APPEARANCE: ANALYSIS FROM A RANDOMIZED TRIAL (2021) (0)
S1330 High Discovery Rate of Previously Undiagnosed Patients With Eosinophilic Gastritis and Duodenitis Using a Systematic Endoscopic Biopsy Protocol: Screening Data Analysis From ENIGMA, a Randomized Controlled Trial (2020) (0)
Cyclosporine and FK 506 Differentially Regulate the Sarcolemmal Na 1K 1 Pump (2001) (0)
Abstract 14686: Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Once-Daily ZS-9 for Treatment of Hyperkalemia: Achievement and Maintenance of K+ in Subgroup Analysis of Patients with Significant Renal Impairment and Heart Failure (2014) (0)
The Role of Metalloprotease Inhibitors in Cancer and Chronic Inflammatory Diseases (2000) (0)
Abstract 635: Achievement of Normokalemia with ZS-9 Across Subgroups in a Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Patients with Hyperkalemia (2014) (0)
New Agents for Hyperkalemia REPLY (2015) (0)
278 PRIMARY RESULTS OF A PHASE 1 MULTICENTER OPEN-LABEL STUDY OF ANTOLIMAB, AN ANTI-SIGLEC-8 ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH CHRONIC GASTROINTESTINAL SYMPTOMS AND ELEVATED GASTRIC AND/OR DUODENAL MAST CELLS (2020) (0)
Abstract 17489: Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Once-Daily ZS-9 for Treatment of Hyperkalemia: Achievement and Maintenance of K+ in Subgroup Analysis of Patients with Heart Failure not on RAAS Inhibitors (2014) (0)
Trends in Opioid Analgesic Abuse and Mortality in the United States (2015) (0)
Electrophysiologic Profile and Efficacy of Intravenous Do#efWe/e UK-68,798), a New Class III Antiarrh I 63 mic Patients with Sustaine Drug, in Monomorphic Ventricular Tachycardia (1995) (0)
P-004. A novel use of β3 adrenergic receptor agonist in treating preeclampsia (2021) (0)
Heart Failure and CardiomyopathiesACHIEVEMENT OF NORMOKALEMIA IN HEART FAILURE PATIENTS NOT ON RENIN:ANGIOTENSIN:ALDOSTERONE SYSTEM INHIBITORS: POOLED ANALYSIS FROM TWO PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE:BLIND, PLACEBO:CONTROLLED TRIALS OF SODIUM ZIRCONIUM CYCLOSILICATE FOR TREATMENT OF HYPERK (2016) (0)
Maintenance of normokalemia with sodium zirconium cyclosilicate (ZS-9) in patients with heart failure on RAAS inhibitors: Subgroup analysis of a phase 3, randomized, placebo-controlled trial (2015) (0)
851 Long Term Angiographic Follow-Up of Saphenous Vein Graft Interventions Using Distal Embolisation Protection Devices (2020) (0)
ACELL September 46/3 (1999) (0)
Normalization of Serum Potassium With Sodium Zirconium Cyclosilicate (ZS-9) in Patients With Heart Failure (2015) (0)
Predictors of Radiation Exposure During ST Elevation Myocardial Infarction (STEMI) (2019) (0)
[Magnesium and cardiovascular disease. II. The significance of magnesium deficiency for cardiovascular disease]. (1988) (0)
Angiographic Predictors of Coronary Haemodynamics: The FFR Is Not Affected by Lesion Length or Location (2018) (0)
RARE SALAMI trial revisited (2002) (0)
228 INTERIM RESULTS OF AN OPEN-LABEL EXTENSION STUDY OF ANTOLIMAB, AN ANTI-SIGLEC-8 ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH EOSINOPHILIC GASTRITIS AND/OR EOSINOPHILIC ENTERITIS (2020) (0)
Stimulation of β3 Adrenergic Signalling Reverses Diabetes-Induced Oxidative Inhibition of Sarcolemmal Na+–K+ pump (2013) (0)
PKA inhibits the Na+–K+pump in cadiac myocytes via superoxide (2006) (0)
S3146 Patients With Eosinophilic Esophagitis (EoE) and Persistent Extra-Esophageal GI Symptoms Should Be Evaluated for Eosinophilic Gastritis (EG) and Eosinophilic Duodenitis (EoD) (2020) (0)
621 PL02.05 LONG-TERM TREATMENT OF PATIENTS WITH EOSINOPHILIC GASTRITIS AND/OR EOSINOPHILIC DUODENITIS WITH LIRENTELIMAB, A MONOCLONAL ANTIBODY AGAINST SIGLEC-8 (2021) (0)
Prediction of Outcome in Acute Renal Failure bv Discriminant Analysis of Clinical Variables (1986) (0)
Targeting cardiac myocyte Na+-K+ pump function with β3 adrenergic agonist in rabbits and patients with severe congestive heart failure (2019) (0)
High pressure treatment of foods (1998) (0)
Abstract 508: Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Once-Daily ZS-9 for Treatment of Hyperkalemia: Maintenance of Serum K + in Subgroup Analysis of Patients on RAAS Therapy (2014) (0)
Siglec—8, a Novel Selective Target for Eosinophilic Gastrointestinal Diseases (EGIDs) Found on Eosinophils and Mast Cells in Human Tissue (2018) (0)
PKA/PKC cross-talk mediates NADPH oxidase-induced Na+–K+ pump inhibition in cardiac myocytes (2007) (0)
Left Bundle Branch Block without superadded ST elevation is rarely associated with significant myocardial injury in the setting of field triage to primary angioplasty (2009) (0)
Oxidative inhibition of erythrocyte Na+-K+ pump in diabetes: A functionally relevant circulating marker of oxidative stress (2012) (0)
832 Graft Versus Native Vessel Intervention for Patients With Previous Bypass Surgery Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (2020) (0)
Dependence of Na (cid:1) -K (cid:1) pump current-voltage relationship on intracellular Na (cid:1) , K (cid:1) , and Cs (cid:1) in rabbit cardiac myocytes (2002) (0)
VENTRICULAR PREMATURE BEATS INDUCED BY CONTRAST ECHOCARDIOGRAPHY IN AN ANIMAL MODEL (2003) (0)

This paper list is powered by the following services:

Other Resources About Hjalte Rasmussen

en.wikipedia.org

What Schools Are Affiliated With Hjalte Rasmussen?

Hjalte Rasmussen is affiliated with the following schools: